Suppr超能文献

强直性脊柱炎患者影像学损害的进展:明确韧带骨赘的核心作用

Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes.

作者信息

Baraliakos X, Listing J, Rudwaleit M, Haibel H, Brandt J, Sieper J, Braun J

机构信息

Rheumazentrum Ruhrgebiet, Landgrafenstr 15, 44652 Herne, Germany.

出版信息

Ann Rheum Dis. 2007 Jul;66(7):910-5. doi: 10.1136/ard.2006.066415. Epub 2007 Feb 28.

Abstract

BACKGROUND

Structural changes such as erosions, syndesmophytes and ankylosis are characteristic of ankylosing spondylitis (AS). These can be quantified by the modified Stokes Anklylosing Spondylitis Spinal Score (mSASSS). It is unknown which radiographic feature is most relevant for the assessment of change and the prediction of future damage in AS.

OBJECTIVES

To analyse radiographic progression in AS by using different assessments to define the most important changes.

METHODS

Spinal radiographs of 116 patients with AS were scored by the mSASSS at baseline (BL) and after 2 years. Radiographic progression was assessed by differentiating (1) any change; (2) progression to syndesmophytes/ankylosis (definite change); and (3) changes exceeding the smallest detectable change (SDC) as predefined. A growth angle of 45 degrees was used to differentiate syndesmophytes from spondylophytes.

RESULTS

Some radiographic progression after 2 years was detected in 42% of patients, novel syndesmophytes in 31% of patients, and, using the SDC (calculated at 2 mSASSS units) as cut-off, progression was seen in 28% of patients. Thus, in 74% of the patients changes were because of syndesmophytes and/or ankylosis. Using the predefined cut-off, only 12% of all syndesmophytes were spondylophytes. Patients with such changes were of older age. Definite radiographic progression was found in 44% of the patients with syndesmophytes/ankylosis at BL (n = 57) versus 19% (p = 0.03) of the patients without such changes (n = 59).

CONCLUSIONS

Syndesmophytes and ankylosis are the most relevant structural changes in AS, and also in the mSASSS. Development of just one syndesmophyte within 2 years indicates progression of structural changes in AS; this is relevant for clinical practice. Syndesmophytes are the best predictors of radiographic progression.

摘要

背景

诸如骨侵蚀、韧带骨赘和关节强直等结构变化是强直性脊柱炎(AS)的特征。这些可通过改良斯托克斯强直性脊柱炎脊柱评分(mSASSS)进行量化。目前尚不清楚哪种影像学特征对于评估AS的变化及预测未来损害最为相关。

目的

通过使用不同评估方法来分析AS的影像学进展,以确定最重要的变化。

方法

对116例AS患者的脊柱X线片在基线(BL)时和2年后进行mSASSS评分。通过区分以下情况评估影像学进展:(1)任何变化;(2)进展为韧带骨赘/关节强直(明确变化);(3)变化超过预先定义的最小可检测变化(SDC)。采用45度的生长角度来区分韧带骨赘和椎体骨赘。

结果

42%的患者在2年后检测到一些影像学进展,31%的患者出现新的韧带骨赘,以SDC(计算为2个mSASSS单位)为界值,28%的患者出现进展。因此,74%的患者的变化是由于韧带骨赘和/或关节强直。使用预先定义的界值,所有韧带骨赘中只有%是椎体骨赘。有此类变化的患者年龄较大。在基线时存在韧带骨赘/关节强直的患者中,44%(n = 57)出现明确的影像学进展,而无此类变化的患者中这一比例为19%(p = 0.03)(n = 59)。

结论

韧带骨赘和关节强直是AS中以及mSASSS中最相关的结构变化。2年内仅出现一个韧带骨赘表明AS结构变化进展;这对临床实践具有重要意义。韧带骨赘是影像学进展的最佳预测指标。

相似文献

1
Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes.
Ann Rheum Dis. 2007 Jul;66(7):910-5. doi: 10.1136/ard.2006.066415. Epub 2007 Feb 28.
4
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab.
Rheumatology (Oxford). 2007 Sep;46(9):1450-3. doi: 10.1093/rheumatology/kem166. Epub 2007 Jul 10.
7
Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study.
Ann Rheum Dis. 2015 Jan;74(1):52-9. doi: 10.1136/annrheumdis-2013-204055. Epub 2013 Aug 16.

引用本文的文献

2
Disease-specific definitions of new bone formation on spine radiographs: a systematic literature review.
Rheumatol Adv Pract. 2024 May 24;8(2):rkae061. doi: 10.1093/rap/rkae061. eCollection 2024.
3
Bone metabolism and inflammatory biomarkers in radiographic and non-radiographic axial spondyloarthritis patients: a comprehensive evaluation.
Front Endocrinol (Lausanne). 2024 Feb 15;15:1227196. doi: 10.3389/fendo.2024.1227196. eCollection 2024.
4
Atlas for the CT Syndesmophyte Score (CTSS) in patients with axial spondyloarthritis.
RMD Open. 2024 Jan 10;10(1):e003702. doi: 10.1136/rmdopen-2023-003702.
6
New Bone Formation in Axial Spondyloarthritis: A Review.
Rofo. 2024 Jun;196(6):550-559. doi: 10.1055/a-2193-1970. Epub 2023 Nov 9.
9
The Epidemiology and Treatment of Ankylosing Spondylitis in Korea.
J Rheum Dis. 2022 Oct 1;29(4):193-199. doi: 10.4078/jrd.22.0023. Epub 2022 Sep 22.

本文引用的文献

1
The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year.
Ann Rheum Dis. 2006 Aug;65(8):1038-43. doi: 10.1136/ard.2005.045658. Epub 2006 Jan 26.
5
Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides.
Scand J Rheumatol. 2005 May-Jun;34(3):178-90. doi: 10.1080/03009740510026599.
6
Therapy of ankylosing spondylitis--a review. Part I: Conventional medical treatment and surgical therapy.
Scand J Rheumatol. 2005 Mar-Apr;34(2):97-108. doi: 10.1080/03009740510018679.
8
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
Ann Rheum Dis. 2005 Feb;64(2):229-34. doi: 10.1136/ard.2004.025130. Epub 2004 Sep 23.
10
Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change.
Ann Rheum Dis. 2005 Feb;64(2):179-82. doi: 10.1136/ard.2003.018457. Epub 2004 Jul 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验